ELI LILLY AND COMPANY Effective Income Tax Rate Reconciliation, Tax Credit, Amount
ELI LILLY AND COMPANY (LLY) reported Effective Income Tax Rate Reconciliation, Tax Credit, Amount of $327.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCredits · last filed 2026-02-12
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, amount for fiscal 2025 was $327.00M, a 12.37% increase from fiscal 2024.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, amount for fiscal 2024 was $291.00M, a 12.79% increase from fiscal 2023.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, amount for fiscal 2023 was $258.00M, a 66.45% increase from fiscal 2022.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, tax credit, amount for fiscal 2022 was $155.00M, a 54.23% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $327.00M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $291.00M 10-K · filed 2026-02-12 | $290.60M 10-K · filed 2025-02-19 |
| 2023-12-31 | $258.00M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $155.00M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $100.50M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $97.90M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $108.80M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $87.40M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $66.80M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $57.00M 8-K · filed 2019-10-24 | $58.30M 10-K · filed 2017-02-21 |
| 2015-12-31 | $69.20M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $44.30M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $175.60M 10-K · filed 2016-02-19 | |
| 2012-12-31 | $11.20M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $80.80M 10-K · filed 2014-02-19 | |
| 2010-12-31 | $83.20M 10-K · filed 2013-02-21 | -$83.20M 10-K · filed 2011-02-22 |
| 2009-12-31 | $79.40M 10-K · filed 2012-02-24 | -$79.40M 10-K · filed 2011-02-22 |
| 2008-12-31 | -$58.00M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |